SCHEMBL2092290

SCHEMBL2092290

COc1cc(OC)c(-c2nc(C[O])no2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
ALDH1A1 P00352 6/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
TP53 P04637 3/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
RPS6KB1 P23443 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
L3MBTL1 Q9Y468 5/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Difucol Hexamethyl Ether SCHEMBL505203 0.65 CYP1A2 (0.60) LMNASMN1; SMN2ALDH1A1CYP1A2CYP3A4
SCHEMBL2092500 0.65 ALDH1A1 (0.44) LMNAHPGDALDH1A1CYP1A2CYP3A4
SCHEMBL1047857 0.65 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1CYP1A2CYP3A4CA1
SCHEMBL656828 0.61 ALDH1A1 (0.61) LMNATSHRMEN1KMT2AHPGD
SCHEMBL8868853 0.61 RAB9A (0.45) TSHRMEN1HTTKMT2AHPGD
SCHEMBL4865554 0.61 NOTUM (0.68) LMNAHTTHPGDSMN1; SMN2ALDH1A1
SCHEMBL29159184 0.61 ALDH1A1 (0.43) LMNAHTTSMN1; SMN2ALDH1A1CYP1A2
SCHEMBL17684661 0.61 ALDH1A1 (0.61) LMNAHPGDSMN1; SMN2ALDH1A1CYP1A2
SCHEMBL13049389 0.61 NPC1 (0.61) TSHRMEN1KMT2AHPGDSMN1; SMN2
SCHEMBL658771 0.61 RPS6KB1 (0.47) LMNAHTTHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 LMNA 4594/4885TSHR 162/4885MEN1 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.